Terms: = Cervical cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
69 results:
1. Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells.
Quiros-Fernandez I; Libório-Ramos S; Leifert L; Schönfelder B; Vlodavsky I; Cid-Arregui A
J Med Virol; 2024 May; 96(5):e29630. PubMed ID: 38659368
[TBL] [Abstract] [Full Text] [Related]
2. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted car-T cell therapy: a case report.
Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
[TBL] [Abstract] [Full Text] [Related]
3. Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
Filipas DK; Labban M; Beatrici E; Stone BV; Qian Z; D Andrea V; Ludwig TA; Reis LO; Cole AP; Trinh QD
Vaccine; 2024 Jan; 42(3):441-447. PubMed ID: 38184391
[TBL] [Abstract] [Full Text] [Related]
4. Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment.
Wang A; Wang Y; Du C; Yang H; Wang Z; Jin C; Hamblin MR
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189058. PubMed ID: 38113952
[TBL] [Abstract] [Full Text] [Related]
5. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract] [Full Text] [Related]
6. T cell immunotherapy for cervical cancer: challenges and opportunities.
Yu L; Lanqing G; Huang Z; Xin X; Minglin L; Fa-Hui L; Zou H; Min J
Front Immunol; 2023; 14():1105265. PubMed ID: 37180106
[TBL] [Abstract] [Full Text] [Related]
7. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
Zou Y; Xu Y; Chen X; Zheng L
Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
[TBL] [Abstract] [Full Text] [Related]
8. Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.
Zheng X; Gu H; Cao X; Pan B; Xiang H; Ju M; Xu S; Zheng M
Front Immunol; 2023; 14():1113369. PubMed ID: 36875089
[TBL] [Abstract] [Full Text] [Related]
9. Highlights into historical and current immune interventions for cancer.
Cole K; Al-Kadhimi Z; Talmadge JE
Int Immunopharmacol; 2023 Apr; 117():109882. PubMed ID: 36848790
[TBL] [Abstract] [Full Text] [Related]
10. Engineered T cell therapy for viral and non-viral epithelial cancers.
Norberg SM; Hinrichs CS
Cancer Cell; 2023 Jan; 41(1):58-69. PubMed ID: 36400016
[TBL] [Abstract] [Full Text] [Related]
11. care pathways at end-of-life for cancer decedents: registry based analyses of the living situation, healthcare utilization and costs for all cancer decedents in Norway in 2009-2013 during their last 6 months of life.
Bjørnelv G; Hagen TP; Forma L; Aas E
BMC Health Serv Res; 2022 Oct; 22(1):1221. PubMed ID: 36183057
[TBL] [Abstract] [Full Text] [Related]
12. Generation and Functional Characterization of PLAP car-T Cells against cervical cancer Cells.
Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
[TBL] [Abstract] [Full Text] [Related]
13. Factors associated with cervical cancer screening among women aged 25-60 years in Lao People's Democratic Republic.
Phaiphichit J; Paboriboune P; Kunnavong S; Chanthavilay P
PLoS One; 2022; 17(4):e0266592. PubMed ID: 35390098
[TBL] [Abstract] [Full Text] [Related]
14. Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive cervical cancer.
Jiang Y; Gu H; Zheng X; Pan B; Liu P; Zheng M
Pathol Oncol Res; 2021; 27():1609946. PubMed ID: 34992504
[No Abstract] [Full Text] [Related]
15. car-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid cancer.
Li H; Zhou X; Wang G; Hua D; Li S; Xu T; Dong M; Cui X; Yang X; Wu Y; Cai M; Liao X; Zhang T; Yang Z; Du Y; Li X
J Clin Endocrinol Metab; 2022 Mar; 107(4):1110-1126. PubMed ID: 34751400
[TBL] [Abstract] [Full Text] [Related]
16. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities.
Xu Y; Jiang J; Wang Y; Wang W; Li H; Lai W; Zhou Z; Zhu W; Xiang Z; Wang Z; Zhu Z; Yu L; Huang X; Zheng H; Wu S
Front Immunol; 2021; 12():725330. PubMed ID: 34386017
[TBL] [Abstract] [Full Text] [Related]
17. Is stress related to the presence and persistence of oncogenic human papillomavirus infection in young women?
Kuebler U; Fischer S; Mernone L; Breymann C; Abbruzzese E; Ehlert U
BMC Cancer; 2021 Apr; 21(1):419. PubMed ID: 33863301
[TBL] [Abstract] [Full Text] [Related]
18. High neutrophil-to-lymphocyte ratio is a predictor of short-term survival for patients with recurrent cervical cancer after radiation-based therapy.
Taguchi A; Nakajima Y; Furusawa A; Yoshino Y; Takao M; Kashiyama T; Kino N; Yasugi T
J Obstet Gynaecol Res; 2021 May; 47(5):1862-1870. PubMed ID: 33611808
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
Han X; Liu S; Yang G; Hosseinifard H; Imani S; Yang L; Maghsoudloo M; Fu S; Wen Q; Liu Q
Gynecol Oncol; 2021 Jan; 160(1):351-360. PubMed ID: 33092868
[TBL] [Abstract] [Full Text] [Related]
20. Reducing Socioeconomic Disparities in Comprehensive Smoke-Free Rules among Households with Children: A Pilot Intervention Implemented through a National cancer Program.
Parks MJ; Kegler MC; Kingsbury JH; Borowsky IW
Int J Environ Res Public Health; 2020 Sep; 17(18):. PubMed ID: 32957658
[TBL] [Abstract] [Full Text] [Related]
[Next]
